CellaVision's analyzer important tool in innovative telediagnostic project in Germany

2007-10-31 - English

Dr Andreas Weimann of Charité, medical faculty at the Berlin University Hospitals, is this year's winner of the prestigious German healthcare prize, the Richard Merten Preis. He is awarded the prize for his work on improving and economizing the communication of medical results between three laboratory units of the Berlin University Hospitals. Using CellaVision products, the project has resulted in an improved workflow and more standardized test results.
"Without CellaVision's excellent products I would never have been able to carry out this project and promote and advance it," says Dr Andreas Weimann. "Using telehaematology I have been able to strengthen the cooperation within and between laboratories and make the laboratory workflow a lot more efficient."
When the three laboratory units of the three University Hospitals in Berlin merged, CellaVision's products for routine analysis of blood and quality assurance became an important factor for the success of Dr Andreas Weimann's project. The hospital invested in a modern IT solution with products from CellaVision and Sysmex in order to lower costs while also strengthening online communication between information systems and instruments at the laboratories. Regardless of physical location, it is possible for the laboratory personnel to assess and diagnose samples online.
"We congratulate Dr Weimann on receiving this prize, and are of course very pleased that our products have helped him in creating improved, cost-efficient communication between the laboratory units in Berlin," says Yvonne Mårtensson, CEO of CellaVision.
The Richard Merten Preis is a distinction that rewards prominent medical projects that aim to quality assure and develop German healthcare using modern IT-solutions. The prize of € 10 000 is rewarded annually by the Richard-Merten-Preis foundation. For more information, visit www.richard-merten-preis.de
The prize will be handed over today, Wednesday the October 31, at a ceremony in Frankfurt.
Read the Richard Merten Preis committee's abstract of the project by pressing the link below.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 286 44 00. E-mail: yvonne.martensson@cellavision.com
About Charité
Charité - Universitätsmedizin Berlin is Europe's largest university hospital with 7 500 students, 15 000 employees, and over 1 million patients. The hospital offers both highly specialised and basic healthcare as well as research and education. For more information, visit www.charite.de
About CellaVision
CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy.
The company headquarters are in Lund, Sweden. The company also has subsidiaries Jupiter, Fl, USA, and Toronto, ON, Canada. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.

PDF version: Richard Merten Preis 2007 (in German)

Subscribe to updates

It's possible to subscribe to CellaVision's press releases, financial information by e-mail and SMS.

Click here to register

Information request

Are you looking for some particular information about our company or our business?

Click here to get in touch


ABG Sundal Collier AB
Sten Gustafsson
+46 8 566 286 93

Pareto Securities AB
Christian Lee
+46 8 402 52 67


Access our Student Resources

To access this resource, please provide the following information about yourself.